Polish public radio looks at the upsides and downsides of taking Wegovy as a daily pill instead of a weekly shot.
Recap by typeshit. Full story at www.polskieradio.pl.
8:09
Regan Archibald gives his take on the timeline for retatrutide reaching patients. Tap through for his view on where the drug stands.
Morse says bar and restaurant workers have seen younger adults drink less, framing it as a broad change in the alcohol industry.
Bazaar India's new issue looks at collagen loss and skin laxity concerns tied to fast GLP-1 weight loss, and how beauty brands are responding.
Novo also reported 25% average weight loss in women on CagriSema in a post-hoc trial analysis, while BMO flagged Ozempic losing US share.
Bikman argues the facial change reflects rapid weight loss in general and suggests using the drug as a short-term aid for carb cravings. His view, not settled fact.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
Loading…